Taaffe J, Zhong S, Goldin S, Rawlings KS, Cowling. An overview of influenza H5 vaccines. Lancet Respir Med. 2025 Mar 13:S2213-2600(25)00052
Pandemic influenza remains a significant global health threat, as signalled by the circulation and cross-species transmission of avian influenza A(H5N1) viruses from the clade 2.3.4.4b, including among dairy cattle in the USA since 2024. Although most of the reported human infections from the USA so far have been mild, the virus can change its profile rapidly. To reduce mortality and morbidity from influenza in humans, vaccines remain the most important intervention.
As part of ongoing work related to pandemic prevention and preparedness, WHO held a consultation on public health risk mitigation through A(H5N1) vaccines in September, 2024, which reviewed licensed H5 vaccines using publicly available and informally gathered information. As of September, 2024, there are at least 20 H5 influenza vaccines licensed by regulatory bodies in the Americas, Asia, Australia, and Europe. Most of these vaccines use inactivated influenza virus platforms and are produced from chicken eggs. Additionally, most are adjuvanted with squalene-based adjuvants or aluminium-based. All vaccines follow a two-dose schedule, with ten vaccines additionally indicated for children as young as six months and adults ages 65 years and older. So far, only one country (Finland) has implemented an A(H5) vaccination programme for at-risk groups.
As part of ongoing work related to pandemic prevention and preparedness, WHO held a consultation on public health risk mitigation through A(H5N1) vaccines in September, 2024, which reviewed licensed H5 vaccines using publicly available and informally gathered information. As of September, 2024, there are at least 20 H5 influenza vaccines licensed by regulatory bodies in the Americas, Asia, Australia, and Europe. Most of these vaccines use inactivated influenza virus platforms and are produced from chicken eggs. Additionally, most are adjuvanted with squalene-based adjuvants or aluminium-based. All vaccines follow a two-dose schedule, with ten vaccines additionally indicated for children as young as six months and adults ages 65 years and older. So far, only one country (Finland) has implemented an A(H5) vaccination programme for at-risk groups.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 6 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 6 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 7 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 7 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 7 hours ago
[Go Top] [Close Window]


